Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Farsang C  
Moxonidine: Clinical Profile

Journal of Clinical and Basic Cardiology 2001; 4 (3): 197-200

PDF    Summary   

Keywords: HypertonieI1-RezeptorenImidazolinagonistKardiologieMoxonidincardiologyhypertensionI1 receptorsimidazoline agonistsmoxonidine

Several haemodynamic, humoral, and metabolic changes develop in patients with hypertension. Antihypertensive drugs inhibiting or reversing these alterations are of clinical value in the therapy of hypertension. Among these agents, most recently the imidazoline I1 receptor agonists can also be considered as the first therapeutic option. Moxonidine is a selective I1 receptor agonist with a pharmacokinetic profile that enables it to be used once daily. It inhibits the consequences of the increased sympathetic tone, it increases natriuresis, and therefore effectively decreases blood pressure in a wide variety of hypertensive patients. The particular advantage of moxonidine is that it can increase the insulin sensitivity of those patients where it is decreased, therefore it is useful in hypertensive patients with insulin resistance. Moxonidine can be combined with many other antihypertensive drugs such as thiazides, ACE-inhibitors, calcium antagonists, but it can be potentially useful in combinations with alpha1-blockers, angiotensin AT1 blockers, and, in a particular group of patients, with beta-blockers (patients with exaggerated sympathetic tone, or in those with hyperthyroidism).
copyright © 2003–2018 Krause & Pachernegg GmbH | Sitemap | Impressum